Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (NCT05254171)
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Who can join: Review the eligibility criteria below.
Location: Genesis Cancer and Blood Institute (SCRI) — Hot Springs, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (93 Sites)
Showing the first 25 of 93 sites.
- Genesis Cancer and Blood Institute (SCRI) — Hot Springs, Arkansas
- Providence Medical Foundation — Fullerton, California
- Yale Cancer Center — New Haven, Connecticut
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Henry Ford Health System — Detroit, Michigan
- CentraCare Health — Saint Cloud, Minnesota
- Columbia University Medical Center — New York, New York
- University of Rochester — Rochester, New York
- Mark H Zangmeister Center - SCRI - PPDS — Columbus, Ohio
- Tennessee Oncology NASH - SCRI - PPDS — Nashville, Tennessee
- HOPE Cancer Center of East Texas — Tyler, Texas
- Medical Oncology Associates - Spokane — Spokane, Washington
- MultiCare Regional Cancer Center - Tacoma — Tacoma, Washington
- Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
- Canberra Region Cancer Centre — Garran, Australia Capital Territory
- The Tweed Hospital — Tweed Heads, New South Wales
- Ashford Cancer Centre Research — Kurralta Park, South Australia
- Austin Hospital — Heidelberg, Victoria
- St John of God Murdoch Hospital — Murdoch, Western Australia
- Klinikum Klagenfurt Am Woerthersee — Klagenfurt, Carinthia
- Universitätsklinikum St. Pölten — Sankt Pölten, Lower Austria
- Ordensklinikum Linz, Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H — Linz, Upper Austria
- Pyhrn-Eisenwurzen Klinikum Steyr — Steyr, Upper Austria
- Klinikum Wels-Grieskirchen GmbH — Wels, Upper Austria
- Landeskrankenhaus Feldkirch — Rankweil, Vorarlberg
📞 Contact the Study Coordinator
Phone: (952) 479-1196
Email: rbragg@panbela.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Cancer Metastatic
- Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC — Boston, Massachusetts
- Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer — Brooklyn, New York
Explore by condition: All Pancreatic Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.